Search research articles
Contact Us
Filters
Showing results (261-270 of 466) with videos related to
Page
of 47
Sort By:
British Journal of Haematology
|
June 20, 2008
Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis
Tiemo Katzenberger, Dirk Kienle, Stephan Stilgenbauer, et al.
Leukemia
|
June 24, 2025
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice
Piers Blombery, Thomas Chatzikonstantinou, Marina Gerousi, et al.
Blood
|
August 20, 2009
Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells
Till Seiler, Manuela Woelfle, Sophia Yancopoulos, et al.
Haematologica
|
May 9, 2020
Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study
Franck Morschhauser, Kamal Bouabdallah, Stephan Stilgenbauer, et al.
Blood
|
June 4, 2021
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations
Paula Cramer, Eugen Tausch, Julia von Tresckow, et al.
Cellular and Molecular Life Sciences : CMLS
|
September 22, 2023
Loss of ORP3 induces aneuploidy and promotes bladder cancer cell invasion through deregulated microtubule and actin dynamics
Xue Wang, Junnan Liu, Anca Azoitei, et al.
Leukemia & Lymphoma
|
August 20, 2021
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor
Philipp Bernhard Staber, Wojciech Jurczak, Richard Greil, et al.
Cancer Discovery
|
May 11, 2021
Discovery of Candidate DNA Methylation Cancer Driver Genes
Heng Pan, Loïc Renaud, Ronan Chaligne, et al.
International Journal of Cancer
|
September 19, 2017
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib
Christine Wolf, Angela Garding, Katharina Filarsky, et al.
Leukemia & Lymphoma
|
November 24, 2022
Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients
Nadine Kutsch, Emily Eva Holmes, Sandra Robrecht, et al.
Page
of 47
Search research articles
Search
Showing results (261-270 of 466) with videos related to
Sort By:
Page
of 47
British Journal of Haematology
|
June 20, 2008
Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis
Tiemo Katzenberger, Dirk Kienle, Stephan Stilgenbauer, et al.
Leukemia
|
June 24, 2025
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice
Piers Blombery, Thomas Chatzikonstantinou, Marina Gerousi, et al.
Blood
|
August 20, 2009
Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells
Till Seiler, Manuela Woelfle, Sophia Yancopoulos, et al.
Haematologica
|
May 9, 2020
Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study
Franck Morschhauser, Kamal Bouabdallah, Stephan Stilgenbauer, et al.
Blood
|
June 4, 2021
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations
Paula Cramer, Eugen Tausch, Julia von Tresckow, et al.
Cellular and Molecular Life Sciences : CMLS
|
September 22, 2023
Loss of ORP3 induces aneuploidy and promotes bladder cancer cell invasion through deregulated microtubule and actin dynamics
Xue Wang, Junnan Liu, Anca Azoitei, et al.
Leukemia & Lymphoma
|
August 20, 2021
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor
Philipp Bernhard Staber, Wojciech Jurczak, Richard Greil, et al.
Cancer Discovery
|
May 11, 2021
Discovery of Candidate DNA Methylation Cancer Driver Genes
Heng Pan, Loïc Renaud, Ronan Chaligne, et al.
International Journal of Cancer
|
September 19, 2017
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib
Christine Wolf, Angela Garding, Katharina Filarsky, et al.
Leukemia & Lymphoma
|
November 24, 2022
Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients
Nadine Kutsch, Emily Eva Holmes, Sandra Robrecht, et al.
Page
of 47